Introduction and Objective: A real-world assessment of the 1-year implantable Eversense 365 CGM System was conducted in adults with diabetes using open-loop insulin regimens.Methods: Anonymized sensor glucose (SG) data from the Eversense Data Management System (DMS) for the first 8277 sensors in the US were used to compare glucometrics from the 1st and 2nd 6-months of Eversense 365 use and the 180-day Eversense E3 CGM System (E3). Mean SG, glucose management indicator (GMI), percent time in glycemic ranges and percent achieving hypoglycemic targets, and median 24-hr transmitter wear time were calculated.Results: Eversense 365 users had a mean age of 56 yrs; 36% male, 27% female, 37% not reported/other; 24% T1D, 58% T2D and 18% not reported. There was a mean of 39076 ± 30174 CGM readings/sensor. Mean SG and GMI were 160.9 mg/dL and 7.2% (Table). Mean % time of SG values in glycemic ranges was 0.6% (<54 mg/dL), 2.7% (<70 mg/dL), 66.1% (≥70 to 180 mg/dL), 31.1% (>180 mg/dL), and 9.9% (>250 mg/dL). Median transmitter wear time was 93.7%. Percent achieving hypoglycemia goals was >79%. Performance of Eversense 365 was consistent between the 1st and 2nd 180-day periods and with E3.Conclusion: Evaluation of the Eversense 365 CGM System in a large patient sample using open-loop insulin regimens confirmed patient adherence and excellent glucometrics, indicating its contribution to effective diabetes management with essentially one sensor over a year time period.
S. Han: Employee; Current; Senseonics. Stock/Shareholder; Current; Senseonics. K. Davis: None. C.E. Mdingi: Employee; Current; Senseonics. F.R. Kaufman: Employee; Current; Senseonics.
Source link
Leave a Reply